FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1866302376> ?p ?o ?g. }

• W1866302376 endingPage "1478" @default.
• W1866302376 startingPage "1470" @default.
• W1866302376 abstract "PURPOSE A phase I trial was undertaken to determine the toxicity and biologic effects of a combination of murine monoclonal antibody L6 (MoAb L6) plus subcutaneous (SC) interleukin-2 (IL-2). PATIENTS AND METHODS Fifteen patients with refractory adenocarcinoma (five breast, five lung, five colorectal), received L6 at 200 mg/m2 intravenously (IV) daily on days 1 to 7, followed by a 1-week rest period. IL-2 was given at either 2, 3, or 4.5 x 10(6) U/m2 daily doses times 4 days for a total duration of 3 weeks. RESULTS Side effects of L6 consisted of mild fever and chills along with a rash and serum sickness in one patient. One patient developed dyspnea and urticaria, that resolved with antihistamines. Maximum-tolerated dose (MTD) of SC IL-2 was 3 x 10(6) U/m2, with dose-limiting toxicities that consisted of grade 4 fatigue and dyspnea. Significant decreases in complement levels along with increases in absolute lymphocyte count and eosinophil count were observed. Mean antibody-dependent cellular cytotoxicity from mononuclear cells taken from patients who received IL-2 was elevated significantly compared with baseline in all patients independent of IL-2 dose (P less than .05). Serum IL-2 levels were elevated in 13 of 14 patients (range, 0.9 to 100 U/mL). Human antimouse antibody (HAMA) titers were elevated in nine of 14 (64%) patients who were tested between 3 and 8 weeks after L6 infusion. One patient with breast cancer had a transient mixed response, and one patient with colorectal cancer had a partial response. CONCLUSIONS L6 and SC IL-2 were well tolerated in the majority of patients when given in the outpatient setting. In view of the clinical efficacy of this combination, more phase II trials are warranted." @default.
• W1866302376 created "2016-06-24" @default.
• W1866302376 creator A5003696197 @default.
• W1866302376 creator A5011338529 @default.
• W1866302376 creator A5020656427 @default.
• W1866302376 creator A5034428180 @default.
• W1866302376 creator A5040300976 @default.
• W1866302376 creator A5040316381 @default.
• W1866302376 creator A5042276749 @default.
• W1866302376 creator A5059714974 @default.
• W1866302376 creator A5076602611 @default.
• W1866302376 creator A5084899987 @default.
• W1866302376 date "1992-09-01" @default.
• W1866302376 modified "2023-09-27" @default.
• W1866302376 title "Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung." @default.
• W1866302376 cites W1553293727 @default.
• W1866302376 cites W1576667077 @default.
• W1866302376 cites W1583511232 @default.
• W1866302376 cites W1602601100 @default.
• W1866302376 cites W1843453924 @default.
• W1866302376 cites W1862901090 @default.
• W1866302376 cites W1904436785 @default.
• W1866302376 cites W1980846395 @default.
• W1866302376 cites W2045863333 @default.
• W1866302376 cites W2102016301 @default.
• W1866302376 cites W2113009157 @default.
• W1866302376 cites W2129386723 @default.
• W1866302376 cites W2146132517 @default.
• W1866302376 cites W2149724818 @default.
• W1866302376 cites W2154330641 @default.
• W1866302376 cites W2155221651 @default.
• W1866302376 cites W2257187839 @default.
• W1866302376 cites W2262779158 @default.
• W1866302376 cites W2268560405 @default.
• W1866302376 cites W2322553446 @default.
• W1866302376 doi "https://doi.org/10.1200/jco.1992.10.9.1470" @default.
• W1866302376 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1517790" @default.
• W1866302376 hasPublicationYear "1992" @default.
• W1866302376 type Work @default.
• W1866302376 sameAs 1866302376 @default.
• W1866302376 citedByCount "33" @default.
• W1866302376 countsByYear W18663023762012 @default.
• W1866302376 countsByYear W18663023762015 @default.
• W1866302376 crossrefType "journal-article" @default.
• W1866302376 hasAuthorship W1866302376A5003696197 @default.
• W1866302376 hasAuthorship W1866302376A5011338529 @default.
• W1866302376 hasAuthorship W1866302376A5020656427 @default.
• W1866302376 hasAuthorship W1866302376A5034428180 @default.
• W1866302376 hasAuthorship W1866302376A5040300976 @default.
• W1866302376 hasAuthorship W1866302376A5040316381 @default.
• W1866302376 hasAuthorship W1866302376A5042276749 @default.
• W1866302376 hasAuthorship W1866302376A5059714974 @default.
• W1866302376 hasAuthorship W1866302376A5076602611 @default.
• W1866302376 hasAuthorship W1866302376A5084899987 @default.
• W1866302376 hasConcept C126322002 @default.
• W1866302376 hasConcept C2778570526 @default.
• W1866302376 hasConcept C2778594517 @default.
• W1866302376 hasConcept C29730261 @default.
• W1866302376 hasConcept C71924100 @default.
• W1866302376 hasConcept C90924648 @default.
• W1866302376 hasConceptScore W1866302376C126322002 @default.
• W1866302376 hasConceptScore W1866302376C2778570526 @default.
• W1866302376 hasConceptScore W1866302376C2778594517 @default.
• W1866302376 hasConceptScore W1866302376C29730261 @default.
• W1866302376 hasConceptScore W1866302376C71924100 @default.
• W1866302376 hasConceptScore W1866302376C90924648 @default.
• W1866302376 hasIssue "9" @default.
• W1866302376 hasLocation W18663023761 @default.
• W1866302376 hasLocation W18663023762 @default.
• W1866302376 hasOpenAccess W1866302376 @default.
• W1866302376 hasPrimaryLocation W18663023761 @default.
• W1866302376 hasRelatedWork W2038518800 @default.
• W1866302376 hasRelatedWork W2050936608 @default.
• W1866302376 hasRelatedWork W2080673841 @default.
• W1866302376 hasRelatedWork W2105212912 @default.
• W1866302376 hasRelatedWork W2134645375 @default.
• W1866302376 hasRelatedWork W2342030892 @default.
• W1866302376 hasRelatedWork W2502996778 @default.
• W1866302376 hasRelatedWork W2729877513 @default.
• W1866302376 hasRelatedWork W2986892476 @default.
• W1866302376 hasRelatedWork W3017145691 @default.
• W1866302376 hasVolume "10" @default.
• W1866302376 isParatext "false" @default.
• W1866302376 isRetracted "false" @default.
• W1866302376 magId "1866302376" @default.
• W1866302376 workType "article" @default.